^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted antibody-drug conjugate

    Related drugs:
    15h
    DREAMM 13: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (clinicaltrials.gov)
    P1, N=0, Withdrawn, GlaxoSmithKline | N=28 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Blenrep (belantamab mafodotin-blmf)
    16d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025
    Enrollment closed • Trial completion date
    |
    lenalidomide • bortezomib • melphalan • Blenrep (belantamab mafodotin-blmf)
    18d
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=20, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    23d
    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, GlaxoSmithKline
    New P2 trial
    |
    bortezomib • carfilzomib • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    23d
    Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=6, Terminated, M.D. Anderson Cancer Center | Trial completion date: May 2027 --> Nov 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2027 --> Nov 2025; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Blenrep (belantamab mafodotin-blmf)
    28d
    DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=208, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2029 --> Mar 2027 | Trial primary completion date: Feb 2029 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Jemperli (dostarlimab-gxly) • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998
    30d
    ALANIS: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, GlaxoSmithKline
    New P2 trial
    |
    bortezomib • cyclophosphamide • Blenrep (belantamab mafodotin-blmf)
    1m
    SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell. (PubMed, Clin Lymphoma Myeloma Leuk)
    The main determinant of second-line therapy selection includes refractoriness, particularly to lenalidomide and anti-CD38 monoclonal antibodies, followed by cytogenetic risk, relapse aggressiveness, frailty, and patient preferences...Combinations based on belantamab mafadotin, an antibody drug conjugate targeting B cell maturation antigen (BCMA), are currently the leading non CAR-T options in this setting, while exportin-1 inhibitors, such as selinexor, and next-generation proteasome inhibitors offer additional options. Ongoing trials assessing T-cell redirecting bispecific antibodies targeting B cell maturation antigen or GPRC5D may further improve outcomes at first relapse as access and safety profiles evolve. In conclusion, early-relapse multiple myeloma care should be individualized in order to optimize patient outcomes and achieve long-term remissions with acceptable toxicity profile.
    Review • Journal
    |
    XPO1 (Exportin 1)
    |
    lenalidomide • Xpovio (selinexor) • Blenrep (belantamab mafodotin-blmf)
    2ms
    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    2ms
    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM (clinicaltrials.gov)
    P1/2, N=25, Active, not recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Blenrep (belantamab mafodotin-blmf) • feladilimab (GSK3359609)
    3ms
    EMN27: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P2, N=35, Completed, Stichting European Myeloma Network | Active, not recruiting --> Completed
    Trial completion
    |
    Blenrep (belantamab mafodotin-blmf)
    3ms
    Corneal events with mirvetuximab soravtansine : A review of ocular surface events associated with the tubulin-acting antibody-drug conjugate, mirvetuximab soravtansine (PubMed, Ophthalmologie)
    Ocular adverse events (AEs) are common among ADCs with tubulin-targeted active agents, such as belantamab mafodotin, tisotumab vedotin and mirvetuximab soravtansine (MIRV). Support from ophthalmologists is essential to AE management to allow MIRV therapy to continue. This review provides ophthalmologists with a clinical overview of ocular AEs associated with certain tubulin-acting ADCs, with a focus on MIRV, and the prophylactic/mitigative measures that can allow patients to stay on MIRV therapy longer.
    Review • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    Elahere (mirvetuximab soravtansine-gynx) • Blenrep (belantamab mafodotin-blmf) • Tivdak (tisotumab vedotin-tftv)